Literature DB >> 26240743

Right ventricle failure associated wıth trastuzumab.

Nermin Bayar1, Selçuk Küçükseymen2, Sevil Göktaş3, Şakir Arslan2.   

Abstract

Trastuzumab (TZ), a monoclonal antibody against human epidermal growth factor receptor type 2 (HER2), is an important biological agent used for the treatment of positive breast cancer. This paper presents a 46-year-old female patient who developed right heart failure and right ventricular dysfunction while on TZ due to breast cancer, and returned to normal following the discontinuation of the drug. As far as we know, this is the first case report related to a patient presenting with right ventricular dysfunction and induced cardiotoxicity while on TZ.

Entities:  

Keywords:  cardiotoxicity; right ventricle failure; trastuzumab

Year:  2015        PMID： 26240743      PMCID： PMC4519740          DOI： 10.1177/2042098615582162

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN： 2042-0986


  10 in total

1.  Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines.

Authors:  D Bovelli; G Plataniotis; F Roila
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

2.  Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: a prospective study using novel cardiac imaging and biochemical markers.

Authors:  Suchi Grover; Darryl P Leong; Adhiraj Chakrabarty; Lucas Joerg; Dusan Kotasek; Kerry Cheong; Rohit Joshi; Majo X Joseph; Carmine DePasquale; Bogda Koczwara; Joseph B Selvanayagam
Journal:  Int J Cardiol       Date:  2013-08-02       Impact factor: 4.164

3.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

4.  The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.

Authors:  Nazanin Fallah-Rad; Jonathan R Walker; Anthony Wassef; Matthew Lytwyn; Sheena Bohonis; Tielan Fang; Ganhong Tian; Iain D C Kirkpatrick; Pawan K Singal; Marianne Krahn; Debjani Grenier; Davinder S Jassal
Journal:  J Am Coll Cardiol       Date:  2011-05-31       Impact factor: 24.094

5.  Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy.

Authors:  Stefan A Lange; Bernd Ebner; Astrid Wess; Matthias Kögel; Mieczyslaw Gajda; Thomas Hitschold; Jens Jung
Journal:  Clin Res Cardiol       Date:  2012-01-17       Impact factor: 5.460

6.  Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.

Authors:  Daniela Cardinale; Alessandro Colombo; Maria T Sandri; Giuseppina Lamantia; Nicola Colombo; Maurizio Civelli; Giovanni Martinelli; Fabrizio Veglia; Cesare Fiorentini; Carlo M Cipolla
Journal:  Circulation       Date:  2006-11-13       Impact factor: 29.690

7.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

8.  Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

Authors:  Mark D Pegram; Tadeusz Pienkowski; Donald W Northfelt; Wolfgang Eiermann; Ravi Patel; Pierre Fumoleau; Eleonor Quan; John Crown; Deborah Toppmeyer; Michael Smylie; Alessandro Riva; Sandra Blitz; Michael F Press; David Reese; Mary-Ann Lindsay; Dennis J Slamon
Journal:  J Natl Cancer Inst       Date:  2004-05-19       Impact factor: 13.506

9.  Trastuzumab-induced myocardiotoxicity mimicking acute coronary syndrome.

Authors:  K B Ribeiro; C H Miranda; J M Andrade; L G Galli; D G Tiezzi; H F Oliveira; F E Zola; G Volpe; A Pazin-Filho; F M Peria
Journal:  Case Rep Oncol       Date:  2012-03-17

10.  Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring.

Authors:  A L Jones; M Barlow; P J Barrett-Lee; P A Canney; I M Gilmour; S D Robb; C J Plummer; A M Wardley; M W Verrill
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640
  10 in total
  1 in total

1.  Trastuzumab-Induced Cardiomyopathy and Intermittent Left Bundle Branch Block.

Authors:  Hassan Tahir; Nikky Bardia; Kulwant Bath; Yasir Ahmed; Muhammad Rafique; Bassam Omar; Christopher Malozzi
Journal:  Cardiol Res       Date:  2019-07-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.